Related Experiment Video

Updated: Jul 5, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

Maria Roussou1, Efstathios Kastritis, Magdalini Migkou

  • 1Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, Sophias, Greece.

Leukemia & Lymphoma
|May 9, 2008
PubMed
Abstract

Insights

Bortezomib-based regimens show promise for multiple myeloma patients with renal failure. These treatments can improve kidney function and are safe, with similar efficacy and toxicity to patients without renal impairment.

Area of Science:

  • Hematology
  • Nephrology
  • Oncology

Background:

  • Renal failure is a significant complication in multiple myeloma, posing management challenges.
  • Limited data exists on the reversibility of renal failure and the safety of novel agents in these patients.

Purpose of the Study:

  • To evaluate the safety and efficacy of bortezomib-based regimens in multiple myeloma patients with renal failure.
  • To assess the kinetics of serum creatinine and the reversibility of renal failure.

Main Methods:

  • A study of 20 consecutive patients with newly diagnosed or relapsed/refractory multiple myeloma and renal failure (serum creatinine ≥ 2 mg/dl).
  • Patients received bortezomib in combination with dexamethasone or other agents (thalidomide, doxorubicin, melphalan).

Main Results:

  • Renal failure reversal occurred in 40% of patients within a median of 17 days.
  • A 50% decrease in serum creatinine was observed in 50% of patients (median 35 days), with some creatinine decrease in 85%.
  • Objective response rate was 65%, and toxicities were comparable to patients without renal impairment.

Conclusions:

  • Bortezomib-based regimens are safe and effective for multiple myeloma patients with renal impairment.
  • These regimens can improve serum creatinine levels and reverse renal failure in a significant proportion of patients.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...